CyanVac

Executive Summary

CyanVac is a privately-held biotechnology company developing intranasal viral vector vaccines based on its proprietary parainfluenza virus 5 (PIV5) platform. Founded in 2014 and headquartered in Athens, Georgia, the company aims to create easy-to-administer, transport, and manufacture vaccines that block disease transmission. The PIV5 platform enables the delivery of vaccine antigens directly to the respiratory mucosa, potentially inducing both systemic and mucosal immunity, which could be critical for preventing infection and spread of respiratory pathogens. CyanVac's lead programs are focused on respiratory infections, including COVID-19 and respiratory syncytial virus (RSV), but the platform could be applied to other infectious diseases. The company's intranasal approach differentiates it from injectable vaccines by offering needle-free administration and improved logistical convenience. While CyanVac has not yet advanced candidates into clinical trials, its technology has shown promise in preclinical studies, positioning it for potential IND-enabling activities.

Upcoming Catalysts (preview)

• Q4 2026IND submission for lead intranasal vaccine candidate (COVID-19 or RSV)60% success
• Q3 2026Peer-reviewed publication of key preclinical efficacy and safety data70% success
• 2027Strategic partnership or licensing deal with a larger pharmaceutical company50% success